Stem Cells and Cellular Therapies in Lung Biology and Lung Diseases

描述(由申请人提供)： 利用干细胞修复和再生病变肺是治疗各种肺部疾病的一种令人兴奋的潜在治疗方法。越来越多的信息表明，正常情况下不在肺内的细胞可以被招募到肺内，并参与损伤后结构和功能的修复和重塑。与此同时，使用人工基质作为三维肺再生框架的生物工程研究也出现了激增。将这些研究与那些利用干细胞和/或细胞疗法的研究相结合，是一个有希望的快速发展方向，但仍处于起步阶段。与这些研究进一步平行的是，人们对驻留在肺中的干细胞和/或祖细胞参与肺发育以及肺损伤后修复和重塑的分子和细胞事件的了解显著增加。 2005年7月，由NHBLI和囊性纤维化基金会赞助，我们在佛蒙特大学举办了一场名为“成人干细胞、肺生物学和肺病”的会议，相关研究人员以及感兴趣的年轻教职员工和学生齐聚一堂，讨论和讨论这个快速发展的领域的问题。这次会议非常成功，产生了一系列关于基础研究和翻译研究的指导方针，供调查人员和资助机构使用。这次会议也推动了NHBLI RFA《HL-07-003，肺干细胞合作研究》的召开 生物学和基于细胞的治疗“。 随着干细胞和细胞疗法治疗肺部疾病的研究继续快速发展，我们建议再次召集相关调查人员以及来自NHLBI、FDA和非营利性呼吸系统疾病基金会的代表再次辩论和讨论当前的问题。特别要讨论的一个领域是基础研究和转化性研究之间的平衡，以及临床试验在这一领域的作用。与去年夏天的会议一样，初级调查人员和学生(研究生、博士后、研究员)将特别有针对性地参加会议讨论以及 在招贴会上。作为一项新功能，学生们将能够基于对海报摘要的盲目审查来竞争旅游奖项。 会议计划于2007年7月在佛蒙特州大学举行。潜在参与者的热情已经很高了。我们预计，这次会议将再次促进广泛的讨论和辩论，并将显著指导干细胞和肺部疾病细胞疗法的基础和临床研究的方向。

DESCRIPTION (provided by applicant): Repair and regeneration of diseased lung with stem cells is an exciting potential therapeutic approach for a variety of lung diseases. Increasing information suggests that cells normally not resident in the lung can be recruited to the lung and participate in structural and functional repair and remodeling after injury. In parallel, there has been a surge in bioengineering studies investigating use of artificial matrices as framework for three-dimensional lung regeneration. The combination of these studies with those utilizing stem cells and/or cell therapies is a promising rapidly developing direction but one that is still in its infancy. These studies have been further paralleled by significant increases in understanding the molecular and cellular events by which stem and/or progenitor cells resident in the lung participate in both lung development and in repair and remodeling after lung injury. We held a conference at the University of Vermont in July 2005, "Adult Stem Cells, Lung Biology, and Lung Disease", sponsored by the NHBLI and Cystic Fibrosis Foundation, that brought together relevant investigators as well as interested junior faculty and students to debate and discuss issues in this rapidly moving field. This conference was very successful and resulted in a series of guidelines for basic and translation research to be utilized by both investigators and by funding agencies. The meeting also was the impetus for an NHBLI RFA "HL-07-003, Collaborative Studies on Lung Stem Cell Biology and Cell Based Therapy". As studies of stem cell and cell therapies for lung diseases continues to move at a rapid pace, we propose to again convene the relevant investigators as well as representatives from the NHLBI, FDA, and non-profit Respiratory Disease Foundations to again debate and discuss current issues. One area in particular to be discussed is the balance between basic and translational research and the role of clinical trials in this area. As in last summer's conference, junior investigators and students (graduate, post-doctoral, fellow) will be particularly targeted for inclusion in both conference discussions as well as in poster sessions. As a new feature, students will be able to compete for travel awards based on blinded review of poster abstracts. The conference is planned for July 2007 at the University of Vermont. Enthusiasm is already high among potential participants. We anticipate that this conference will again foster extensive discussion and debate and will significantly guide the directions taken in basic and clinical research of stem cells and cell therapies for lung diseases.